Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

27.15 -0.37 (-1.34%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >

Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday ↗

June 22, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout ↗

June 22, 2023

The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis.

Via Investor's Business Daily

5 Analysts Have This to Say About Roivant Sciences ↗

June 08, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023 ↗

June 08, 2023

Via Benzinga

Why Shares of Roivant Sciences Jumped This Week ↗

April 20, 2023

The company's stock benefited from another company's buyout.

Via The Motley Fool

Analyst Expectations for Roivant Sciences's Future ↗

March 16, 2023

Via Benzinga

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission ↗

May 16, 2023

Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old...

Via Benzinga

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug? ↗

April 23, 2023

Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so.

Via The Motley Fool

These 2 Growth Stocks Might Be Incredibly Undervalued Right Now ↗

April 20, 2023

These two biopharma stocks could be poised for a major growth spurt.

Via The Motley Fool

Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years ↗

March 15, 2023

Via Benzinga

Expert Ratings for Roivant Sciences ↗

February 13, 2023

Via Benzinga

Roivant Sciences's Earnings Outlook ↗

February 10, 2023

Via Benzinga

Where Roivant Sciences Stands With Analysts ↗

January 19, 2023

Via Benzinga

EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis ↗

April 17, 2023

While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up.

Via Benzinga

These 3 Nasdaq Stocks Are on Fire Today: Here's Why ↗

April 17, 2023

A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.

Via The Motley Fool

Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom ↗

April 17, 2023

Merck is branching into immune-mediated diseases with this takeover.

Via Investor's Business Daily

Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

April 17, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93...

Via Benzinga

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗

March 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

Via InvestorPlace

Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 21, 2023

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.

Via Benzinga

Why Shares of Roivant Sciences Were Down Tuesday ↗

March 21, 2023

After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.

Via The Motley Fool

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Immunovant Could Potentially Be An M&A Target, Writes Analyst ↗

February 15, 2023

Via Benzinga

Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data ↗

February 14, 2023

Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.

Via Benzinga

Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate ↗

January 04, 2023

Via Benzinga

Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday ↗

December 19, 2022

Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on...

Via Benzinga

Earnings Scheduled For February 13, 2023 ↗

February 13, 2023

Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million.

Via Benzinga

Why Roivant Sciences' Shares Are Up Thursday ↗

December 01, 2022

The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis.

Via The Motley Fool

Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90% ↗

November 15, 2022

Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in...

Via Benzinga

Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94% ↗

November 15, 2022

Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

Headline News about Roivant Sciences Ltd. - Common Shares

Starting at $3.75/week.

Subscribe Today